Halaven

Active Ingredient(s): Eribulin Mesylate
FDA Approved: * November 15, 2010
Pharm Company: * EISAI INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Halaven Overview

Eribulin is an anticancer drug marketed by Eisai Co. under the trade name Halaven. Eribulin is also known as E7389 and ER-086526, and also carries the US NCI designation NSC-707389. It is used to treat certain patients with breast cancer and liposarcoma. Contents 1 Intellectual Property 2 Approvals and indications 2.1 Breast cancer 2.2 Liposarcoma 3 Clinical trials 4 Research and development 5 Structure and mechanism 6 References 7 External links Intellectual Property Currently th...

Read more Halaven Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Eribulin

Recent Halaven Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Eribulin Mesylate
  • Solution: 1mg/2ml (0.5mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Halaven: (1 result)

Sorted by National Drug Code
  • 62856-389 Halaven .5 mg/ml Intravenous Injection by Eisai Inc.

Other drugs which contain Eribulin Mesylate or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 26 April 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA